Here, we revealed that Lgals3bp is an endogenous negative regulator of TAK1 in the colon and suggest that Lgals3bp induction or use of the Lgals3bp-based peptide might be a potential therapeutic approach for IBD and colon cancer. Here, LGALS3BP is linked to colonic neoplasm.